​

The country has its own patent law, and the end of them generally differs from that of other countries.

In this article, we will list which molecules will have their patents broken in 2022, 2023 and 2024.

Brazil Path Pharma is ready to help international companies to seek partners in Brazil, as well as national companies to do the opposite.

This is the “core” of our company and together we will do good business.

Molecules that will lose patents in 2022:

• METFORMIN+ SITAGLIPTIN

• SITAGLIPTIN

• RALTEGRAVIR

• SILTUXIMAB

Molecules that will lose patents in 2023

· PALBOCYCLIB

• PAG ELTHROME

• LINAGLIPTIN

• NILOTIB

• BRIMONIDINE+ TIMOLOL

• LINAGLIPTIN+METFORMIN

• LORCASERIN

Molecules that will lose their patent in 2024

• LISDEXAMETAMINE

• INSULIN DEGLUDEC

• CRIZOTINIB